Lynk Pharmaceuticals Reports Favorable Long-Term Trial Data for Rheumatoid Arthritis Drug

Lynk Pharmaceuticals reported positive long-term Phase III trial results for its oral JAK1 inhibitor, zemprocitinib, in adult patients with moderate-to-severe rheumatoid arthritis. The study demonstrated sustained improvements in disease activity and physical function through Week 76, offering a potential new treatment for those with inadequate response to existing biologic therapies.